Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,533

Human Aging REVERSED In New Medical Breakthrough

Human aging has been reversed in a new medical breakthrough. John Iadarola, Brooke Thomas, and Greg Fahy break it down on The Damage Report. Follow The Damage Report on Facebook: https://www.facebook.com/TheDamageReportTYT/

Help build the Home of the Progressives http://tyt.com/JOIN

Follow The Damage Report on Twitter: https://twitter.com/TheDamageReport

“A small clinical trial, which was conducted by a team of researchers led by Dr. Greg Fahy, has shown for the first time in humans that reversing biological age may be possible.

The results of TRIIM are in.

Scientists extend mice lifespan 12%

Scientists successfully extended the average lifespan of mice by breeding them using embryonic stem cells with extra-long telomeres. The findings are significant because the researchers managed to extend lifespan without genetic modification, and they also shed light on the aging process and techniques that might someday slow it.

The study — published October 17 in Nature Communications — focuses on telomeres, which are stretches of DNA found at the end of chromosomes.

Because telomeres protect the genetic material inside chromosomes, they’ve been likened to the plastic tips on the ends of shoelaces. But telomeres have also been compared to bomb fuses, or “molecular clocks,” because they become shorter each time a cell divides, eventually shrinking so much that the cell dies or stops dividing. This shortening of our telomeres is associated with aging, cancer, and death.

Physics of windshield-cracking raindrops could demolish kidney stones

A plane has to be going pretty fast for a mere raindrop to crack its windshield, but it can happen. Now, new models of the physics behind the improbable feat may just help doctors crack kidney stones to pieces.

When supersonic jets were first being developed for commercial use in the 1960s, researchers discovered a curious phenomenon that sometimes occurs on test flights through rainforests. Even though raindrops weigh almost nothing, they are capable of creating ring-shaped cracks in the jets’ substantial windshields.

Although scientists initially had difficulty explaining this curiosity, Professors Frank Philip Bowden and John Field of the University of Cambridge eventually recognized as the culprits. Because surface waves spread in only two dimensions, they pack a much more powerful punch than their three-dimensional counterparts. Certain details of the phenomenon, however, have remained poorly understood due to a lack of mathematics to describe it and experimental setups to validate proposed models.

Forget Growing Weed—Make Yeast Spit Out CBD and THC Instead

Now researchers have turned to yeast to do something more improbable: manufacturing the cannabis compounds CBD and THC. By loading brewer’s yeast with genes from the cannabis plant, they’ve turned the miracle microbes into cannabinoid factories. It’s a clever scheme in a larger movement to methodically pick apart and recreate marijuana’s many compounds, to better understand the plant’s true potential.

Yeast gives us beer and bread. Now researchers have engineered it to do something more improbable: manufacturing the cannabis compounds CBD and THC.

Israeli team develops novel therapy to target advanced cancerous tumors

Holon-based cancer immunotherapy company Compugen disclosed encouraging preliminary results on Tuesday from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target (PVRIG) in patients with advanced solid tumors.

The Nasdaq and Tel Aviv-listed company, a pioneer in predictive drug target discovery, has developed innovative computational discovery platforms to identify new drug targets and subsequently produce first-in-class therapeutics. The clinical trial of the anti-PVRIG antibody, called COM701, aimed to assess the safety of escalating doses of the therapy in patients with advanced solid tumors, but also demonstrated initial signals of anti-tumor activity in the heavily pre-treated patient population enrolled in the study.

“We are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701,” said Compugen president and CEO Dr. Anat Cohen-Dayan.

David Pearce — Experience Machines and Hedonic Treadmills

“…consider Robert Nozick’s thought-experiment in conjunction with Felipe De Brigard’s inverse experience machine argument: “If you like it, does it matter if it’s real?”

Does Nozick’s experience machine prove anything?

Perhaps consider Robert Nozick’s thought-experiment in conjunction with Felipe De Brigard’s inverse experience machine argument: “If you like it, does it matter if it’s real?”

For sure, many subjects say they wouldn’t plug into Nozick’s Experience Machine; but conversely, many of these same respondents claim they wouldn’t want to unplug from an Experience Machine if told their existing lives were based on a lie. In short, maybe what is really being measured is not simply our (lack of) commitment to hedonism or realism, but rather status quo bias.

Even self-avowed classical utilitarians may balk on realising what their own ethics entails.

Continue reading “David Pearce — Experience Machines and Hedonic Treadmills” | >

Drug combination preserves cognitive function in mice with Alzheimer’s disease

A new study from the Johns Hopkins University School of Medicine shows that selectively removing senescent cells—cells that no longer divide—from brains with a form of Alzheimer’s disease can reduce brain damage and inflammation and slow the pace of cognitive decline. These findings, say researchers, add to evidence that senescent cells contribute to the damage caused by Alzheimer’s disease.

“Our results show that eliminating these cells may be a viable route to treat Alzheimer’s disease in humans,” says Mark Mattson, a professor of neuroscience at the School of Medicine and a senior investigator in the Laboratory of Neurosciences at the National Institute on Aging.

A report on the work was published April 1 in Nature Neuroscience.

/* */